Michael Castagna
Chief Executive Officer bei MANNKIND CORPORATION
Vermögen: 6 Mio $ am 31.03.2024
Profil
Michael E.
Castagna is currently the Chief Executive Officer & Director at MannKind Corp.
He is also a Director at Pet Partners.
Previously, he held positions as the Executive Director-Immunology Franchise at Bristol Myers Squibb Co. from 2010 to 2012, Director at Pharmasset, Inc. in 2005-2006, Vice President-Global Commercial at Amgen, Inc. from 2012 to 2016, and Vice President & Head-Biopharmaceuticals at Sandoz, Inc. from 2009 to 2010.
He also served as the VP & Head-North America Biopharmaceuticals at Novartis AG.
Dr. Castagna obtained a doctorate degree from Massachusetts College of Pharmacy & Health Science in 2014, an MBA from The Wharton School of the University of Pennsylvania in 2005, and an undergraduate degree from Philadelphia College of Pharmacy in 2000.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MANNKIND CORPORATION
0,46% | 21.03.2024 | 1 251 317 ( 0,46% ) | 6 Mio $ | 31.03.2024 |
Aktive Positionen von Michael Castagna
| Unternehmen | Position | Beginn |
|---|---|---|
| MANNKIND CORPORATION | Chief Executive Officer | 25.05.2017 |
| Pet Partners | Director/Board Member | - |
Ehemalige bekannte Positionen von Michael Castagna
| Unternehmen | Position | Ende |
|---|---|---|
| AMGEN INC. | Corporate Officer/Principal | 14.03.2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.11.2012 |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 01.11.2010 |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Director/Board Member | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Ausbildung von Michael Castagna
| Massachusetts College of Pharmacy & Health Science | Doctorate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Philadelphia College of Pharmacy | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| MANNKIND CORPORATION | Health Technology |
| NOVARTIS AG | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
| Pet Partners |
